273 research outputs found
Naturschutz und Ökologischer Landbau – auch zukünftig ein win-win-Modell
Die Vorzüglichkeit des Ökologischen Landbaus gegenüber konventioneller Landwirtschaft in seinen Auswirkungen auf den Naturhaushalt ist anhand von Vergleichsuntersuchungen vielfach dokumentiert. Die positiven Aspekte für den Naturschutz drohen jedoch unter ökonomischen Zwängen geringer zu werden. In frühzeitigen Reaktionen gemeinsam mit der Landwirtschaft gilt es, integrative Lösungskonzepte aufzuzeigen, wie Naturschutzbelange in den Ökologischen Landbau integriert werden können bzw. wie neue Wege beschritten werden können, naturschutzfachliche Optimierungen zu erreichen. Die Bemühungen müssen ihren Niederschlag auch im länderübergreifenden Austausch finden
Measurements of complement factor H-related protein (BTA-TRAK (TM) assay) and nuclear matrix protein (NMP22 assay) - Useful diagnostic tools in the diagnosis of urinary bladder cancer?
Between 1997 and 2000 we investigated in a prospective study the voided urine samples of all consecutive patients undergoing cystoscopy independent from their clinical background (n=705) with the BTA-TRAK(TM) assay (Bard Diagnostics, Redmont, USA) detecting complement factor H-related protein (CFHrP) and the NMP22 assay (Matritech, Newton, USA) measuring nuclear matrix protein, which is supposed to be specific for bladder cancer. The individuals were divided into three groups concerning the clinical background: 233 patients had urological diseases, 268 patients had urinary bladder cancer and 150 patients had other urological malignancies. Based on the clinical findings we compared our results with well established diagnostic methods for urinary bladder cancer such as cytology and the detection of hematuria. In addition, we investigated urine samples from 30 healthy individuals and 24 patients with urinary tract infection without performing cystoscopy. Following the recommendations of the European Group on Tumor Markers we used 95% specificity for benign urological diseases and urinary tract infections, which resulted in a sensitivity of 17% for active bladder cancer for the BTA-TRAK(TM) assay and 31% for NMP22. We compared these results with the detection of hematuria (specificity: 72%) and cytology, which had a sensitivity of 64% and 89%, respectively. Subsequently, we calculated sensitivity and specificity for the detection of relapse of the disease. Again using 95% specificity, in this case for patients with no evidence of disease (NED), in patients with recurrent disease the BTA-TRAK(TM) assay showed % sensitivity as compared to 12% for the NMP22 assay. Due to an insufficient specificity and sensitivity, both tests can neither be clinically useful in screening of high risk patients, nor in primary diagnosis of bladder cancer. They cannot replace neither cystoscopy nor cytology. In the follow-up care more investigations may be necessary to prove the benefit of existing diagnostic strategies for the discrimination between active and inactive bladder cancer
SEX-RELATED DIFFERENCES IN THE PHARMACOLOGICAL TREATMENT OF MAJOR DEPRESSION - ARE WOMEN AND MEN TREATED DIFFERENTLY?
Background: In the last decade, sex-related medicine has become an increasingly important area of research as insights in this
field can improve treatment strategies and recovery. The aim of this study was to investigate sex-related differences in the
prescription and kinds of psychopharmacological treatment in individuals with unipolar affective disorder.
Subjects and methods: Data collected on 388 patients attending a psychiatric rehabilitation clinic (194 females, 194 males,
mean age 52.3 years, standard deviation 7.8 years), who were matched by age and severity of depression, were analyzed. Depression
severity and information on drug type and quantity were assessed at the beginning of the rehabilitation program and compared
between women and men.
Results: A significant difference between females and males was found in the frequency of prescribing bupropion (females:
3.61%, males: 12.89%; p=0.001) and mirtazapine (females: 5.15%, males: 13.40%; p=0.005). In terms of polypharmacy, the results
showed that over 53% of the patients were taking two or more psychotropic substances as a long-term therapy and that 34% of them
were taking three to five different substances. No sex-related differences were found concerning the number of psychotropic drugs
taken by the patients.
Conclusion: The higher frequency of prescriptions for bupropion and mirtazapine in men might be explained by the adverse
drug reactions of the drugs (e.g., fewer sexually adverse drug reactions, weight gain) and a known interaction with oral
contraception. It remains unclear whether these aspects are taken into consideration for each patient in terms of their special needs
and conditions or whether it is a decision based on the patient’s sex. Given a similar severity of depression, men and women are
prescribed a similar number of psychotropic substances. However, the high number of psychotropic drugs prescribed on average
should be noted. Well-trained healthcare professionals should focus on regularly assessing and optimizing treatment regimens
Tales from Ginderup Mound in Thisted County, Denmark: Further Investigations of Female Mobility in the Nordic Bronze Age
The preservation of organic and human remains in Early Nordic Bronze Age mounds (1700 BCE -1100 BCE) permits new provenance work on this important period. Studies have shown that different mobility/non-mobility patterns were exercised by elite women during this time. To extend the database, we conducted strontium isotope analyses of the enamel from the second and third molars from the elite female grave from Ginderup in Thisted County, Denmark. Among other items, this grave included the textile remains of a possible corded skirt or fringed blanket. We complemented analyses of this woman’s enamel with strontium isotope analyses of the first molar from Grave B as well as osteological analysis of the individuals from Early Nordic Bronze Age Graves A, B and C.
Our results revealed that the strontium isotope ratios obtained from the woman wearing a possible corded skirt yielded one local ratio (M2) and one non-local ratio (M3). The results from Grave B yielded a ratio which falls within the local baseline of present-day Denmark. Our results suggest that the Ginderup Woman was probably of local origin, but that she also was repeatedly mobile during her life. These data are further evidence for the Nordic Bronze Age’s complex socio-dynamics. 
Recanalization strategies in childhood stroke in Germany
Childhood arterial ischemic stroke (CAIS) is a rare event. Diverse etiologies, risk factors, symptoms and stroke mimics hamper obtaining a fast diagnosis and implementing immediate recanalization strategies. Over a period of 3~years (2015-2017), the data of 164 pediatric patients (> 28~days of life-18~years) with a first episode of AIS were submitted to a hospital-based nationwide surveillance system for rare disorders (ESPED). We report a subgroup analysis of patients who have undergone recanalization therapy and compare these data with those of the whole group. Twenty-eight patients (17%) with a median age of 12.2~years (range 3.3-16.9) received recanalization therapy. Hemiparesis, facial weakness and speech disturbance were the main presenting symptoms. The time from onset of symptoms to confirmation of diagnosis was significantly shorter in the intervention group (4.1~h vs. 20.4~h, p ≤ 0.0001). Only in one patient occurred a minor bleed. Cardiac disease as predisposing risk factor was more common in the recanalization group. Recanalization therapies are feasible and increasingly applied in children with AIS. High awareness, timely diagnosis and a large amount of expertise may improve time to treatment and make hyperacute therapy an option for more patients
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022
Mast cell neoplasms are an emerging challenge in the fields of internal medicine, allergy, immunology, dermatology, laboratory medicine, and pathology. In this review, we discuss the current standards for the diagnosis and prognostication of mast cell neoplasms with special reference to clinically relevant germline and somatic gene variants. In patients with cutaneous mastocytosis or with indolent systemic mastocytosis (SM), various KIT-activating mutations act as key molecular drivers of the disease. In adults, KIT p.D816V is by far the most prevalent driver, whereas other KIT mutants are detected in nearly 40% of children. In advanced SM, including aggressive SM, SM with an associated hematological neoplasm, and mast cell leukemia, additional somatic mutations in other genes, such as SRSF2, JAK2, RUNX1, ASXL1, or RAS, may be detected. These drivers are more frequently detected in SM with an associated hematological neoplasm, particularly in male patients. Recently, hereditary alpha-tryptasemia has been identified as a genetic trait more prevalent in SM compared with healthy controls. Moreover, hereditary alpha-tryptasemia is more frequent in patients with SM with Hymenoptera venom allergy and severe mediator-related symptoms than in patients with SM without symptoms. On the basis of this knowledge, we propose a diagnostic algorithm in which genetic markers are applied together with clinical and histopathologic criteria to establish the diagnosis and prognosis in SM
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis
Background: Advanced systemic mastocytosis (advSM) is characterized by presence of the KIT D816V mutation and pathologic accumulation of neoplastic mast cells (MCs) in various tissues, leading to severe symptoms and organ damage (eg, cytopenias, liver dysfunction, portal hypertension, malabsorption, and weight loss). Treatment with midostaurin, an orally active multikinase/KIT inhibitor now approved for advSM in the United States and the European Union, resulted in a high rate of response accompanied by reduced MC infiltration of the bone marrow and lowered serum tryptase level. Objective: We aimed to determine whether midostaurin improves health-related quality of life (QOL) and MC mediator related symptoms in patients with advSM. Methods: In 116 patients with systemic mastocytosis (89 patients with advSM fulfilling the strict inclusion criteria of the D2201 study [ClinicalTrials.gov identifier NCT00782067]), QOL and symptom burden were assessed during treatment with midostaurin by using the 12-Item Short-Form Health Survey (SF-12) and the Memorial Symptom Assessment Scale patient reported questionnaires, respectively. MC mediator related symptoms were evaluated by using a specific physician-reported questionnaire Results: Over the first 6 cycles of treatment with midostaurin (ie, 6 months), patients experienced significant improvements in total SF-12 and Memorial Symptom Assessment Scale scores, as well as in subscores of each instrument. These improvements were durable during 36 months of follow-up. Similarly, we found substantial improvements (67%-100%) in all MC mediator related symptoms. Conclusion: QOL and MC mediator related symptoms significantly improve with midostaurin treatment in patients with advSM (ClinicalTrials.gov identifier, NCT00782067)
- …